Sun Xiaoxia, Zhang Jian, Wang Lihua, Tian Zhigang
Institute of Basic Medical Sciences, Shandong Academy of Medical Science, 89 Jingshi Road, Jinan 250062, China.
Cancer Lett. 2008 Apr 18;262(2):201-13. doi: 10.1016/j.canlet.2007.12.009. Epub 2008 Jan 11.
More and more studies show that signal transducer and activator of transcription 3 (STAT3) is frequently constitutively activated in a wide number of malignancies and named as an attractive molecular target for tumor treatment. Here, we employed STAT3-decoy ODN, which specifically block over-activated STAT3, to treat human hepatocellular carcinoma (HCC) cells, and evaluated the cellular proliferation ability and investigated the molecular mechanisms in vitro. The results demonstrated that the proliferation of HCC cells was suppressed significantly by STAT3-decoy ODN, being associated with the increased apoptosis and cell arrest at G0/G1 to S phase transition. Further investigates showed the expression of STAT3-regulated genes including bcl-x1, cyclin D1 and c-myc, which involved in cell apoptosis and cell cycle progression, were down-regulated significantly both at transcription and translation levels. These data suggested that STAT3 may be potentially used as a molecular target in HCC therapy.
越来越多的研究表明,信号转导及转录激活因子3(STAT3)在多种恶性肿瘤中经常发生组成性激活,并被视为肿瘤治疗中一个有吸引力的分子靶点。在此,我们采用特异性阻断过度激活的STAT3的STAT3诱饵寡核苷酸(ODN)来处理人肝癌(HCC)细胞,评估细胞增殖能力并在体外研究其分子机制。结果表明,STAT3诱饵ODN显著抑制了HCC细胞的增殖,这与细胞凋亡增加以及细胞在G0/G1期到S期转变时的阻滞有关。进一步研究表明,参与细胞凋亡和细胞周期进程的STAT3调控基因包括bcl-x1、细胞周期蛋白D1和c-myc的表达在转录和翻译水平均显著下调。这些数据表明,STAT3可能有望作为HCC治疗的分子靶点。